

Brilliant Violet 510™ anti-mouse I-A/I-E Antibody

Catalog# / Size	107635 / 125 µL 107636 / 50 µg
Clone	M5/114.15.2
Regulatory Status	RUO
Other Names	MHC class II
Isotype	Rat IgG2b, κ
Description	These class II molecules are expressed on antigen presenting cells (including B cells) and a subset of T cells from H-2 ^{b,d,q,r} bearing mice and are involved in antigen presentation to T cells expressing CD3/TCR and CD4 proteins.

Product Details

Verified Reactivity	Mouse
Antibody Type	Monoclonal
Host Species	Rat
Immunogen	Activated C57BL/6 mouse spleen cells
Formulation	µg & µl: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation	µg & µl: The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 510™ under optimal conditions.
Concentration	µg size: 0.2 mg/mL µL size: lot-specific (to obtain lot-specific concentration, please enter the lot number in our Concentration and Expiration Lookup or Certificate of Analysis online tools.)
Storage & Handling	µg & µl: The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application	FC - Quality tested
Recommended Usage	<p>Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining using µg size, the suggested use of this reagent is ≤ 0.5 µg per million cells in 100 µl volume. For flow cytometric staining using µl size, the suggested use of this reagent is 5 µl per million cells or 5 µl per 100 µl of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.</p> <p>Brilliant Violet 510™ excites at 405 nm and emits at 510 nm. The bandpass filter 510/50 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 510™ is a trademark of Sirigen Group Ltd.</p> <p>Learn more about Brilliant Violet™.</p> <p>This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.</p>
Excitation Laser	Violet Laser (405 nm)
Application Notes	The M5/114.15.2 antibody reacts with a polymorphic determinant shared by the I-A ^b , I-A ^d , I-A ^q , I-E ^d , and I-E ^k MHC class II alloantigens from mice carrying H-2 ^{p,r,q,b,d,u} haplotypes. Clone M5/114.15.2 however does not react with I-A ^f , I-A ^k , or I-A ^s MHC class II alloantigens. ¹

Additional reported applications (for the relevant formats) include: immunoprecipitation¹, immunohistochemistry of frozen sections^{2,3,6}, *in vitro* and *in vivo* blocking of antigen presentation or ligand binding⁴⁻⁷, and spatial biology (IBEX)^{17,18}. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/μg, Azide-Free, 0.2 μm filtered) is recommended for functional assays (Cat. Nos. 107655 & 107656).

Application References

(PubMed link indicates BioLegend citation)

1. Bhattacharya A, *et al.* 1981. *J. Immunol.* 127:2488. (IP)
2. Viville S, *et al.* 1993. *Cell* 72:635. (IHC)
3. Nelson AJ, *et al.* 1993. *J. Immunol.* 151:2453. (IHC)
4. Shi Y, *et al.* 1998. *J. Exp. Med.* 187:367. (Block)
5. Yamashita I, *et al.* 1993. *Int. Immunol.* 5:1139.
6. Guo M, *et al.* 1995. *Zygote* 3:65. (IHC)
7. Kim A, *et al.* 2004. *Exp. Mol. Med.* 36:428. (Block)
8. Luckashenak NA, *et al.* 2006. *J. Immunol.* 177:5177.
9. Venanzi ES, *et al.* 2007. *J. Immunol.* 179:5693.
10. Christensen SR, *et al.* 2006. *Immunity* 25:417. [PubMed](#)
11. Matte-Martone C, *et al.* 2008. *Blood* 111:3884. [PubMed](#)
12. De Pascalis R, *et al.* 2008. *Infect. Immun.* 76:4311. [PubMed](#)
13. Kuns RD, *et al.* 2009. *Blood* 113:5999. [PubMed](#)
14. Sabatino JJ, *et al.* 2011. *J. Exp. Med.* 208:81. [PubMed](#)
15. Draber P, *et al.* 2011. *Mol Cell Biol.* 22:4550. [PubMed](#)
16. Fu H, *et al.* 2014. *Nat Commun.* 5:3436. [PubMed](#)
17. Radtke AJ, *et al.* 2020. *Proc Natl Acad Sci U S A.* 117:33455-65. (SB) [PubMed](#)
18. Radtke AJ, *et al.* 2022. *Nat Protoc.* 17:378-401. (SB) [PubMed](#)

Product Citations

1. Gogoi H, *et al.* 2020. *Front Immunol.* 1.620833333. [PubMed](#)
2. Tan J, *et al.* 2021. *iScience.* 24(8):102835. [PubMed](#)
3. Wenzek C, *et al.* 2022. *iScience.* 25:105540. [PubMed](#)
4. Lefebvre MN, *et al.* 2021. *Cell Rep.* 37:109956. [PubMed](#)
5. Yu K, *et al.* 2021. *Cell Reports.* 35(12):109273. [PubMed](#)
6. Kashyap AS, *et al.* 2019. *Cell Rep.* 28:3367. [PubMed](#)
7. Ogbechi J, *et al.* 2022. *Front Immunol.* 13:1001956. [PubMed](#)
8. Yousif AS, *et al.* 2020. *Immunity.* 54(2):235-246.e5. [PubMed](#)
9. Chikina AS, *et al.* 2020. *Cell.* 183:411. [PubMed](#)
10. Zhu X, *et al.* 2017. *Arch Oral Biol.* 10.1016/j.archoralbio.2017.03.010. [PubMed](#)
11. Yuzhu Hou *et al.* 2018. *Immunity.* 49(3):490-503. [PubMed](#)
12. Diao L, *et al.* 2022. *iScience.* 25:105511. [PubMed](#)
13. Brandt S, *et al.* 2020. *J Am Soc Nephrol.* 31:2589. [PubMed](#)
14. Rao S, *et al.* 2017. *Cell.* 168(3):503-516.e12. [PubMed](#)
15. Si Y, *et al.* 2020. *Sci Adv.* 6:eaba0995. [PubMed](#)
16. Esmaili S, *et al.* 2021. *Cell Systems.* 12(5):432-445.e7. [PubMed](#)
17. Eddy W, *et al.* 2017. *The Journal of Immunology.* 10.4049/jimmunol.1601777. [PubMed](#)
18. Moreau HD *et al.* 2019. *Dev Cell.* 49(2):171-188. [PubMed](#)
19. Perner C, *et al.* 2020. *Immunity.* 53(5):1063-1077.e7. [PubMed](#)
20. Kuhn NF, *et al.* 2020. *Nat Commun.* 4.74375. [PubMed](#)
21. Huggins MA, *et al.* 2019. *Cell Rep.* 28:1729. [PubMed](#)
22. Devalaraja S, *et al.* 2020. *STAR Protoc.* 1:100188. [PubMed](#)
23. Wu X, *et al.* 2021. *Elife.* 10:. [PubMed](#)
24. Salei N, *et al.* 2020. *J Am Soc Nephrol.* 31:257. [PubMed](#)
25. Sato R, *et al.* 2020. *Int Immunol.* 499:32. [PubMed](#)
26. Liu D *et al.* 2019. *Immunity.* 51(1):64-76. [PubMed](#)
27. Kelsey E Sivick *et al.* 2018. *Cell reports.* 25(11):3074-3085. [PubMed](#)
28. Stump CT, *et al.* 2021. *Open Biol.* 11:210245. [PubMed](#)
29. Baasch S, *et al.* 2021. *Cell.* . [PubMed](#)
30. Lim HY *et al.* 2018. *Immunity.* 49(2):326-341. [PubMed](#)
31. Leylek R, *et al.* 2019. *Cell Rep.* 29:3736. [PubMed](#)
32. Garcia LR, *et al.* 2021. *Nat Commun.* 12:3364. [PubMed](#)
33. Huang YL, *et al.* 2021. *Commun Biol.* 4:229. [PubMed](#)
34. Mao FY, *et al.* 2021. *Cell Mol Gastroenterol Hepatol.* 12:395. [PubMed](#)
35. Formaglio P, *et al.* 2021. *Immunity.* 54:2724. [PubMed](#)
36. Sangesland M, *et al.* 2020. *Cell Reports.* 32(8):108065. [PubMed](#)
37. Kennedy EM, *et al.* 2022. *Nat Commun.* 13:5907. [PubMed](#)
38. Chauveau L, *et al.* 2021. *EMBO Rep.* 22:e52447. [PubMed](#)
39. Scur M, *et al.* 2022. *Nat Commun.* 13:7272. [PubMed](#)
40. Lammers K, *et al.* 2015. *PLoS One.* 10: 0138338. [PubMed](#)
41. Ermert D, *et al.* 2016. *PLoS Pathog.* 11: 1005043. [PubMed](#)
42. Stifter SA, *et al.* 2019. *Cell Rep.* 29:3539. [PubMed](#)
43. Liu S, *et al.* 2018. *Front Immunol.* 29:208. [PubMed](#)
44. Monaghan KL, *et al.* 2020. *J Vis Exp.* . [PubMed](#)
45. Alam Z, *et al.* 2020. *Cell Rep.* 107825:31. [PubMed](#)
46. Gamrekashvili J, *et al.* 2021. *Bio Protoc.* 11:e4007. [PubMed](#)
47. Mansouri S, *et al.* 2020. *Mucosal Immunol.* 0.954861111. [PubMed](#)
48. Yasuda T, *et al.* 2016. *PLoS One.* 11:e0167952. [PubMed](#)
49. Hammer A, *et al.* 2017. *Front Immunol.* . 10.3389/fimmu.2017.01922. [PubMed](#)
50. Hollern DP, *et al.* 2020. *Cell.* 179(5):1191-1206.e21.. [PubMed](#)
51. Li E, *et al.* 2021. *Front Immunol.* 12:667177. [PubMed](#)
52. Rosato PC, *et al.* 2019. *Nat Commun.* 10:567. [PubMed](#)

53. Knuplez E, *et al.* 2021. *British Journal of Pharmacology*. 178(5):1234-1248. [PubMed](#)
54. Velazquez VM, *et al.* 2017. *Mol Ther Methods Clin Dev*. 0.277083333. [PubMed](#)
55. Katzmarski N, *et al.* 2021. *Nat Immunol*. 22:1382. [PubMed](#)
56. Truckenbrod EN, *et al.* 2021. *Elife*. 10: . [PubMed](#)
57. Smith KJ, *et al.* 2022. *PLoS Biol*. 20:e3001554. [PubMed](#)
58. Hartwig T *et al.* 2017. *Molecular cell*. 65(4):730-742 . [PubMed](#)
59. Walker JA, *et al.* 2020. *Immunity*. 51(1):104-118. [PubMed](#)
60. Zhang J, *et al.* 2020. *Cell Metabolism*. 31(6):1136-1153. [PubMed](#)
61. Hayashi K, *et al.* 2020. *Nat Commun*. 4.832638889. [PubMed](#)
62. Thomson CA, *et al.* 2018. *J Immunol*. 201:215. [PubMed](#)
63. Kuhn NF *et al.* 2019. *Cancer cell*. 35(3):473-488 . [PubMed](#)

RRID AB_2561397 (BioLegend Cat. No. 107635)
 AB_2734168 (BioLegend Cat. No. 107636)

Antigen Details

Structure	MHC class II
Distribution	B cell and activated T cells, APCs of the H-2 ^{b,d,q,r} bearing mice
Function	Antigen presentation
Ligand/Receptor	CD3/TCR, CD4
Cell Type	Antigen-presenting cells, B cells, Dendritic cells, T cells, Tregs
Biology Area	Immunology, Innate Immunity
Molecular Family	MHC Antigens
Antigen References	1. Watts C. 1997. <i>Ann. Rev. Immunol.</i> 15:821. 2. Pamer E, <i>et al.</i> 1998. <i>Ann. Rev. Immunol.</i> 16:323.
Gene ID	14961 14969


Related Protocols

[Cell Surface Flow Cytometry Staining Protocol](#)

Other Formats

Biotin anti-mouse I-A/I-E, FITC anti-mouse I-A/I-E, PE anti-mouse I-A/I-E, Purified anti-mouse I-A/I-E, PE/Cyanine5 anti-mouse I-A/I-E, APC anti-mouse I-A/I-E, Alexa Fluor® 488 anti-mouse I-A/I-E, Alexa Fluor® 647 anti-mouse I-A/I-E, Pacific Blue™ anti-mouse I-A/I-E, Alexa Fluor® 700 anti-mouse I-A/I-E, PerCP/Cyanine5.5 anti-mouse I-A/I-E, PerCP anti-mouse I-A/I-E, APC/Cyanine7 anti-mouse I-A/I-E, PE/Cyanine7 anti-mouse I-A/I-E, Brilliant Violet 421™ anti-mouse I-A/I-E, Brilliant Violet 510™ anti-mouse I-A/I-E, Purified anti-mouse I-A/I-E (Maxpar® Ready), Brilliant Violet 605™ anti-mouse I-A/I-E, Brilliant Violet 650™ anti-mouse I-A/I-E, Brilliant Violet 711™ anti-mouse I-A/I-E, Brilliant Violet 785™ anti-mouse I-A/I-E, PE/Dazzle™ 594 anti-mouse I-A/I-E, Alexa Fluor® 594 anti-mouse I-A/I-E, APC/Fire™ 750 anti-mouse I-A/I-E, TotalSeq™-A0117 anti-mouse I-A/I-E, Ultra-LEAF™ Purified anti-mouse I-A/I-E, TotalSeq™-B0117 anti-mouse I-A/I-E, TotalSeq™-C0117 anti-mouse I-A/I-E, Spark Blue™ 550 anti-mouse I-A/I-E, PE/Fire™ 640 anti-mouse I-A/I-E, Spark YG™ 581 anti-mouse I-A/I-E, PE/Fire™ 810 anti-mouse I-A/I-E, Spark UV™ 387 anti-mouse I-A/I-E

Product Data



C57BL/6 mouse splenocytes were stained with mouse I-A/I-E (clone M5/114.15.2) Brilliant Violet 510™ (filled histogram) or rat IgG2b, κ Brilliant Violet 510™ isotype control (open histogram).

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587